Login to Your Account



Celgene basks in ozanimod 'SUNBEAM,' though details are still in shadow

By Marie Powers
News Editor

Friday, February 17, 2017

Celgene Corp. reported success in the phase III SUNBEAM trial evaluating the efficacy and safety of ozanimod – the oral selective S1PR1 and 5 S1PR5 receptor modulator that was the crown jewel in its 2015 pick-up of Receptos Inc. – but offered few details.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription